Clinical trial
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C
NCT01889433 is registered in ClinicalTrials.gov with Biocad as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C
- Lead sponsor
- Biocad
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 10, 2013
- Completion date
- December 2, 2015
- Enrollment
- 170 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.